Ethics approval and consent to participate

Patient samples were collected following informed consent approved by our Institutional Review Board at the Dana-Farber Cancer Institute. Animal studies were performed after approval by the Animal Ethics Committee of the DFCI and performed using institutional guidelines.

Consent for publication

All authors have read and approved the final manuscript.

Competing interests

N.C.M. serves on advisory boards or is a consultant to Takeda, BMS, Celgene, Janssen, Amgen, AbbVie, Oncopep, Karyopharm, Adaptive Biotechnology, and Novartis and holds equity ownership in Oncopep. A.M.R. serves on advisory board of Amgen, Celgene, Janssen, and Takeda.  No potential conflicts of interest were disclosed by the other authors.